Table 2.

Baseline characteristics and outcomes

Patient	HBsAg	HBsAb	HBeAg	HBeAb	HBcAb	HBV DNA, IU/mL	ALT, U/L	AST, U/L	Bilirubin total µM	Albumin, G/L	Previous heap hepatitis	Antivira therapy	HBsAg*	HBsAb*	HBeAg*	HBeAb*	HBcAb*	HBV DNA, IU/mL*
1	Negative	Negative	Negative	Positive	Positive	<100	14	23	9.6	33.9	Yes	No	Negative	Positive	Negative	Negative	Positive	<100
2	Negative	Positive	Negative	Negative	Positive	<100	7	13	7.5	34.2	Yes	Entecavir	Negative	Negative	Negative	Negative	Negative	NA
3	Negative	Negative	Negative	Negative	Positive	<100	14	8	15.9	49.6	Yes	Lamivudine	Negative	Positive	Negative	Negative	Positive	<100
4	Negative	Positive	Negative	Positive	Positive	<100	11	12	9.1	42.6	Yes	No	Negative	Positive	Negative	Negative	Negative	<100
5	Negative	Positive	Negative	Negative	Positive	NA	15	18	14.7	40.2	Yes	No	Negative	Positive	Negative	Negative	Negative	NA
6	Positive	Negative	Negative	Positive	Positive	<100	21	32	11.5	38.9	Yes	Entecavir/ Lamivudine	Positive	Negative	Negative	Positive	Positive	<100
7	Negative	Positive	Negative	Positive	Positive	NA	37	20	11.3	36.2	Yes	No	Negative	Positive	Negative	Negative	Negative	<100
8	Negative	Positive	Negative	Negative	Positive	NA	9	15	4.8	36.8	Yes	No	Negative	Positive	Negative	Negative	Positive	NA
9	Negative	Positive	Negative	Negative	Positive	<100	10	15	7.3	41.8	Yes	No	Positive	Negative	Negative	Negative	Positive	<100

*Immunological detection of HBV in serum after BCMA CAR-T infusion in 6 to 12 months.

ALT, alanine transferase; AST, aspartate transaminase; BCMA, B cell maturation antigen; CAR, chimeric antigen receptor; HBcAb, hepatitis B core antibody; HBeAb, hepatitis B e antibody; HBeAg, hepatitis B e antigen; HBsAb, hepatitis B surface antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NA, not applicable.